argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) will report third quarter 2025 financial results and provide a business update via a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET).

Investors can access the live webcast and a replay (available for ~one year) on the company's Investors website at argenx.com/investors. Dial‑in access is available across multiple countries using access code 3810049; participants are asked to dial in 15 minutes before the call.

October 23, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2025 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

Dial-in numbers:

Belgium                32 800 50 201
France                        33 800 943355
Netherlands                31 20 795 1090
United Kingdom        44 800 358 0970
United States                1 888 415 4250
Japan                        81 3 4578 9081
Switzerland                41 43 210 11 32

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

FAQ

When will argenx (ARGX) report its Q3 2025 financial results?

argenx will report Q3 2025 results on October 30, 2025 during a conference call at 1:30 PM CET (8:30 AM ET).

How can investors access the argenx (ARGX) Q3 2025 webcast?

The live audio webcast and a replay (available for about one year) are on the Investors section at argenx.com/investors.

What is the dial‑in access code for argenx (ARGX) October 30, 2025 call?

Use access code 3810049 when joining the call and dial in about 15 minutes before the start time.

What time is argenx (ARGX) Q3 2025 call for US investors?

The call begins at 8:30 AM ET on October 30, 2025.

Will argenx (ARGX) provide a replay of the Q3 2025 webcast?

Yes. A replay of the webcast will be available on the argenx investor website for approximately one year after the presentation.

Which countries have local dial‑in numbers for the argenx (ARGX) Q3 2025 call?

Local dial‑in numbers are provided for Belgium, France, Netherlands, UK, United States, Japan, and Switzerland.